Home World News Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy... World News Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 934 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Allergan Recalls Textured Breast Implants Worldwide Due To Cancer Risk At... July 24, 2019 Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... September 28, 2022 Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations June 15, 2020 Our nurses answer your frequently asked questions about cancer March 2, 2023 Load more HOT NEWS EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... Got the COVID Blues? A cut above: Making drug discovery more efficient using CRISPR What Survivors Should Know When Transitioning From Cancer Care to Primary...
